A246250 Stock Overview
SLS BIO Co., Ltd develops diagnostic technologies in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
SLS BIO Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,970.00 |
| 52 Week High | ₩11,320.00 |
| 52 Week Low | ₩3,955.00 |
| Beta | 0 |
| 1 Month Change | -4.42% |
| 3 Month Change | -4.42% |
| 1 Year Change | -42.01% |
| 3 Year Change | -52.67% |
| 5 Year Change | -17.17% |
| Change since IPO | -1.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| A246250 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 1.4% | -3.7% | -4.3% |
| 1Y | -42.0% | -1.3% | -1.0% |
Return vs Industry: A246250 underperformed the KR Life Sciences industry which returned -1.3% over the past year.
Return vs Market: A246250 underperformed the KR Market which returned -1% over the past year.
Price Volatility
| A246250 volatility | |
|---|---|
| A246250 Average Weekly Movement | 3.6% |
| Life Sciences Industry Average Movement | 7.5% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A246250 has not had significant price volatility in the past 3 months.
Volatility Over Time: A246250's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Lee Young Tae | www.slabs.co.kr |
SLS BIO Co., Ltd develops diagnostic technologies in South Korea. It offers pharmaceuticals quality control testing services, including pharmaceutical equivalence study, raw materials/finished drugs test, and other analysis testing services; and efficacy evaluation services, such as immune function-based efficacy evaluation and pharmacokinetics and toxicokinetics analysis services. In addition, it provides diagnostic kits comprising rapid allergy test, rapid bovine pregnancy diagnosis, and horse individual forensic kits, as well as nano-bio technologies.
SLS BIO Co., Ltd Fundamentals Summary
| A246250 fundamental statistics | |
|---|---|
| Market cap | ₩33.94b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A246250 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A246250 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A246250 perform over the long term?
See historical performance and comparison